Korsana Biosciences is developing CYC-126, a personalized anesthesia treatment for depression that has not responded to standard antidepressants. KRSA reports earnings on Wed, Nov 11, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print.
Prices, price targets and earnings estimates for KRSA are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KRSA is in one of them and how their past KRSA trades turned out.
Korsana Biosciences is a drug developer based in Waltham, Massachusetts, focused on serious neuropsychiatric disorders. Its lead program, CYC-126, is being developed as a treatment for depression that has not responded to at least two antidepressant treatments. The approach combines two widely used anesthetic agents, propofol and dexmedetomidine, with a delivery system that monitors brain activity so dosing can be tailored to each patient. It is designed for use in hospital settings under the care of anesthesiologists. The company is also working to license its older sGC stimulator assets to other firms.
